Resonance Health Ltd · ASX:RHT
Resonance Health — Investor Presentation (October 2026)
29 slides from Resonance Health's investor presentation, Oct 27, 2026
Slide 1: Non-Invasive MRI Liver Fibrosis Device, Preliminary EPoC Study Results & Capital Raising Presentation
rsonal use only N O N - I N V AS I V E M R I L I V E R F I B R O S I S D E V I C E P R E L I M I N AR Y E P O C S T U D Y R E S U L T S & C AP I T AL R AI S I N G P R E S E N T AT I O N | OCTOBER 2026 Funding three growth programmes from a profitable, cash-generative base Andrew Harrison | MD & CEO
Slide 2: Important notice and disclaimer
IMPORTANT NOTICE Important notice and disclaimer rsonal use only Preliminary results. Liver fibrosis results are preliminary and not yet Not an offer. This presentation has been prepared by Resonance Health independently verified, based on 50 subjects from a single site, Ltd (ABN 96 006 762 492) in
Slide 3: A $6.0M placement to fund three growth programmes
THE OFFER A $6.0M placement to fund three growth programmes Placement to institutional, professional and sophisticated investors, within existing Listing Rule 7.1 and 7.1A capacity rsonal use only $6.0M 7.2c 83.3M $10.4M Gross proceeds Offer price per share New shares Pro forma cash Before costs of
Slide 4: Profitable, growing, and funded for the next step
INVESTMENT HIGHLIGHTS Profitable, growing, and funded for the next step rsonal use only Proven growth, now Three businesses, one 1 2 3 Structural tailwinds profitable customer Revenue from $4M in FY23 to $15.8M MRI endpoints, a MASH and metabolic MASH drugs now approved; obesity in FY26, up 42% last
Slide 5: Resonance today
rsonal use only 01 Resonance today A profitable healthcare technology & services group Non-Invasive MRI Liver Fibrosis Device, Preliminary EPOC Trial Results and Capital Raising Presentation 5
Slide 6: Three businesses, one growth path: the pharma trial
THE GROUP Three businesses, one growth path: the pharma trial rsonal use only SaMD core lab Resonance Clinical TrialsWest $7.0M $7.5M $4.1M FY26 revenue | 47% segment margin FY26 revenue | 13% segment margin FY26 revenue | 24% segment margin Regulatory-cleared MRI endpoints: Australian CRO with a MA
Slide 7: Profitable, cash-generative and growing
FY26 PERFORMANCE Profitable, cash-generative and growing rsonal use only FY27 GUIDANCE $15.8M $2.6M $1.5M $17–22M Revenue Normalised EBITDA Statutory NPAT revenue Up 42% on FY25 16% margin Profitable at the statutory line $2.6–3.6M EBITDA $2.9M $2.3M 41% Excludes revenues that may accrue Operating c
Slide 8: Three structural tailwinds
WHY NOW Three structural tailwinds Independent forces converging on the capabilities Resonance Health has spent 20 years building rsonal use only 01 02 03 Liver disease prevalence MASH diagnostics demand GLP-1 trial explosion 1.5B+ 2 951 people living with chronic liver disease FDA-cleared MASH ther
Slide 9: A trial beachhead inside a much larger market
ADDRESSABLE MARKET A trial beachhead inside a much larger market Liver fibrosis assessment, annual market by stage. US only. rsonal use only WIDER LIVER MARKETS ~US$140M ~US$1.3B $23B US$60–100M a year a year hepatic fibrosis market a year (2026) $40B+ CLINICAL TRI ALS, GLOBAL US, DIAGNOSED TODAY US
Slide 10: Liver fibrosis
rsonal use only 02 Liver fibrosis Preliminary results from the extended proof-of- concept study (EPoC) Non-Invasive MRI Liver Fibrosis Device, Preliminary EPOC Trial Results and Capital Raising Presentation 10
Slide 11: Unlocking fibrosis signal from standard MRI
PRELIMINARY RESULTS Unlocking fibrosis signal from standard MRI rsonal use only Significant fibrosis (≥F2) Advanced fibrosis (≥F3) 40 F2–4 vs 10 F0–1 19 F3–4 (incl. one F2–3) vs 31 F0–2 AUC AUC 0.820 0.788 95% CI 0.674–0.940 95% CI 0.631–0.908 Sensitivity (30/40) Sensitivity (11/19) 75.0% 57.9% 95%
Slide 12: What the numbers say, and what they don't yet
INTERPRETATION What the numbers say, and what they don't yet rsonal use only Small cohort, wide A real signal Expands 2022 PoC intervals Both models separate fibrosis stages well The 2022 PoC (AUC 0.92, n = 27) With 10 F0–1 subjects, specificity for ≥F2 above chance, at both thresholds, on 3T separa
Slide 13: Mass access at zero capex for imaging sites
WHERE IT SITS Mass access at zero capex for imaging sites rsonal use only Resonance fibrosis device: no US$0 added costs for hardware or software required at imaging site ~50,000 US$75k–150k MRE: significant cost per scanner, for driver hardware, MRI scanners worldwide sequence and software licence
Slide 14: Three markets, entered in sequence
STRATEGY Three markets, entered in sequence US context: ~460,000 diagnosed F2–F3 MASH patients under specialist care; 6.7M rsonal use only adults with MASH and ≥F2 fibrosis; 267 pharma MASH clinical trials recruiting. STAGE 3 | POST-COVERAGE Reimbursed diagnostics STAGE 2 | POST-CLEARANCE Payer cove
Slide 15: Illustrative investigational use unit economics per trial
ECONOMICS Illustrative investigational use unit economics per trial Revenue = price per scan × patients × MRI visits (number of scans over time) rsonal use only Indicative economics for 3 prevalent clinical trial types (phase 2, 3 & obesity) Revenue per trial (US$M) Paired $6.0M MRI Revenue at Trial
Slide 16: Use of funds
rsonal use only 03 Use of funds Three growth programmes, each funded in full Non-Invasive MRI Liver Fibrosis Device, Preliminary EPOC Trial Results and Capital Raising Presentation 16
Slide 17: Three programmes, each funded in full
USE OF FUNDS Three programmes, each funded in full over 24 months rsonal use only Use $M What it buys Muscle fat and mass, VAT/SAT automation, MRI endpoint acceleration 1.2 validation and clearances TrialsWest east coast First four east coast sites, a dedicated East Coast network 1.5 General Manager
Slide 18: MRI endpoints for the obesity era
PROGRAMME 1 MRI ENDPOINT ACCELERATION | $1.2M MRI endpoints for the obesity era GLP-1 sponsors need muscle and fat-compartment measures next to liver fat. We already sell most of the imaging protocol rsonal use only and are building the rest. What we are building Why it wins Delivery • Muscle fat fr
Slide 19: Metabolic and obesity MRI trial endpoints
PROGRAMME 1 MRI ENDPOINT ACCELERATION | $1.2M Metabolic and obesity MRI trial endpoints Every endpoint in the tiered specification, grouped by region, from one imaging session and one ISO 13485 core lab rsonal use only HEART WHOLE BODY Paracardiac fat epicardial + pericardial volume IN DEV Total adi
Slide 20: The WA site model, replicated on the east coast
PROGRAMME 2 TRIALSWEST EAST COAST NETWORK | $1.5M The WA site model, replicated on the east coast A nine-site national network: three WA sites plus six new east coast sites, run hub-and-spoke from TrialsWest HQ rsonal use only 1 $4.1M FY26 TrialsWest revenue, three WA sites Osborne Park 2 $2M+ Osbor
Slide 21: From preliminary results to an FDA submission
PROGRAMME 3 LIVER FIBROSIS DEVICE | $1.5M From preliminary results to an FDA submission rsonal use only We are here 1 2 3 4 5 6 Complete the Model v2 FDA Pre- Investigational Pivotal validation Submit and clear EPoC Submission use All 68 subjects, Add more data and Agree intended use, Paid analysis
Slide 22: Net cash from $2.3M to $7.9M
PRO FORMA Net cash from $2.3M to $7.9M rsonal use only $M 30 June 2026 Placement Pro forma Cash at bank 4.8 +5.6 10.4 $10.4M pro forma cash NAB facility, drawn (2.5) – (2.5) Funds all three programmes in full, with a $1.4M buffer for contract timing and bolt- Net cash 2.3 +5.6 7.9 on opportunities.
Slide 23: What to watch over the next months
CATALYSTS What to watch over the next 12 to 24 months rsonal use only Liver fibrosis MRI endpoints TrialsWest Group Full EPoC analysis of Muscle quality East Coast General FY27 results against 68 subjects endpoints to market Manager appointed guidance FDA Pre-Submission VAT/SAT automation First east
Slide 24: Offer terms and indicative timetable
OFFER DETAILS Offer terms and indicative timetable rsonal use only Term Detail Event Date $6.0M (before costs), placement to institutional, professional and Trading halt; launch and Fri 23 Oct Offer size sophisticated investors bookbuild Mon 26 Oct 7.2c per share: 12.2% discount to the last close of
Slide 25: Key risks
KEY RISKS Key risks Clinical validation: Preliminary fibrosis results may not be Regulatory: The FDA pathway (510(k) or De Novo), timing and rsonal use only confirmed in the full and final EPoC analysis or in validation. outcome are uncertain; FDA may require more data. Data rights: The validation d
Slide 26: Summary
Summary Profitable and growing: FY26 revenue $15.8M, up 42%, cash rsonal use only 1 positive every quarter. Three growing businesses serving one customer: the pharma 2 trial. 3 $6.0M fully funds the growth strategies across 3 programmes. 4 Liver fibrosis: a real signal on standard MRI, with no addit
Slide 27: Disclaimer & Forward-Looking Statements
Disclaimer & Forward-Looking Statements This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and contains forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actu
Slide 28: Appendix
rsonal use only 04 Appendix Non-Invasive MRI Liver Fibrosis Device, Preliminary EPOC Trial Results and Capital Raising Presentation 28
Slide 29: Board of Directors – Deep Sector Expertise
Board of Directors – Deep Sector Expertise Pharma, clinical, capital markets & commercial depth Aaron Brinkworth Andrew Harrison Dr. David Fuller Michael Sistenich rsonal use only Chairman Managing Director & CEO Non-Executive Director Non-Executive Director 22-year career with Gilead Sciences (Nasd
Resonance Health — Investor Presentation (October 2026) on 6ix